Sanofi says it is looking to resolve the “patchy†accomplishments in the gene therapy space through a new specialized unit that will leverage technologies from its vaccine division. Sanofi has dabbled in the cell and gene therapy over the past decade but is yet to make its mark. Speaking at the JP Morgan Healthcare Conference this week, CEO Paul Hudson highlighted the importance of the sector going forward but admitted industry’s success in the sector has “been patchy.†He told…
Merck & Co. may look to repurpose some US facilities to support production of potential COVID-19 therapy MK-7110. In December 2020, the US Department of Health and Human Services (HHS) struck a $356 million deal with Merck & Co (known as MSD outside North America) to support production of MK-7110, a recombinant protein in Phase III trials as a therapy to treat hospitalized patients with acute COVID-19. When announced, HHS said the Operation Warp Speed (OWS) collaboration was the latest…